

HSV-1 miRNAs are post-transcriptionally edited in latently infected human ganglia

Zubković, Andreja; Gomes, Cristina; Parchure, Adwait; Cesarec, Mia; Ferenčić, Antun; Rokić, Filip; Jakovac, Hrvoje; Whitford, Abigail L.; Dochnal, Sara A.; Cliffe, Anna R.; ...

Source / Izvornik: **Journal of Virology, 2023, 97, 1 - 21**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1128/jvi.00730-23>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:705761>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-11-25**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



Editor's Pick | Virology | Full-Length Text

HSV-1 miRNAs are post-transcriptionally edited in latently infected human ganglia

Andreja Zubković,¹ Cristina Gomes,² Adwait Parchure,¹ Mia Cesarec,¹ Antun Ferenčič,³ Filip Rokić,⁴ Hrvoje Jakovac,³ Abigail L. Whitford,⁵ Sara A. Dochnal,⁵ Anna R. Cliffe,⁵ Dražen Cuculić,³ Angela Gallo,⁶ Oliver Vugrek,⁴ Michael Hackenberg,² Igor Jurak¹

AUTHOR AFFILIATIONS See affiliation list on p. 18.

ABSTRACT Viruses use miRNAs to enable efficient replication, control host defense mechanisms, and regulate latent infection. Herpes simplex virus 1 (HSV-1) expresses multiple miRNAs whose functions are largely unknown. The evolutionary conservation of many HSV-1 miRNAs in the closely related HSV-2 suggests their functional importance. miRNAs, similar to other transcripts, can undergo various post-transcriptional modifications that may affect their biogenesis, stability, and targeting. To investigate whether editing occurs in HSV-1 miRNAs, we sequenced samples from latently infected human ganglia. We show that one of the six HSV-1 miRNAs (miR-H2 to miR-H8) that define HSV-1 latency, miR-H2, exhibits adenosine-to-inosine hyperediting within the miRNA seed sequence. We observed the same specific miR-H2 hyperediting phenomenon in miRNAs isolated from the ganglia of latently infected mice and, to a lesser extent, during productive infection in cultured cells. Curiously, we found no evidence of editing of the encoded HSV-2 homolog in latently infected mice or in cultured cells. The efficient loading of the edited miRNAs onto the RNA-inducing silencing complex indicates their ability to function as miRNAs. To investigate the potential of the edited miRNA to alter mRNA targeting, we predicted the host and viral targets for the modified miRNAs. Nucleotide substitution in the seed region significantly increased the number of potential host and viral targets. Most notably, the mRNA that encodes ICP4, an essential viral protein, was predicted to be an additional target. Using transfection assays, we demonstrated that edited miRNAs have the potential to reduce ICP4 steady-state protein levels in addition to ICP0. Our study identifies a specific hyperedited HSV-1 mRNA, miR-H2, and highlights how the virus can use a single miRNA to target multiple transcripts during persistent, latent infection.

IMPORTANCE Herpes simplex virus 1 is an important human pathogen that has been intensively studied for many decades. Nevertheless, the molecular mechanisms regulating its establishment, maintenance, and reactivation from latency are poorly understood. Here, we show that HSV-1-encoded miR-H2 is post-transcriptionally edited in latently infected human tissues. Hyperediting of viral miRNAs increases the targeting potential of these miRNAs and may play an important role in regulating latency. We show that the edited miR-H2 can target ICP4, an essential viral protein. Interestingly, we found no evidence of hyperediting of its homolog, miR-H2, which is expressed by the closely related virus HSV-2. The discovery of post-translational modifications of viral miRNA in the latency phase suggests that these processes may also be important for other non-coding viral RNA in the latency phase, including the intron LAT, which in turn may be crucial for understanding the biology of this virus.

KEYWORDS HSV-1, miRNA, RNA editing, ADAR, latency, human trigeminal ganglia

Editor Felicia Goodrum, The University of Arizona, Tucson, Arizona, USA

Address correspondence to Igor Jurak, igor.jurak@biotech.uniri.hr.

The authors declare no conflict of interest.

See the funding table on p. 18.

Received 25 May 2023

Accepted 10 July 2023

Published 15 September 2023

Copyright © 2023 American Society for Microbiology. All Rights Reserved.

miRNAs are small non-coding RNAs expressed by plants, animals, and viruses. miRNAs regulate gene expression mainly by binding to partially complementary transcripts and affecting their stability and translation. The specificity of miRNA binding to its target is largely determined by a short sequence at the 5' end of the miRNA molecule (nucleotides 2–8) called the seed [reviewed in references (1–3)]. miRNAs regulate most protein-coding genes and are essential for normal development and growth. On the other hand, deregulated miRNAs are associated with a number of diseases including cancer (4).

Viruses, particularly large DNA viruses, have been found to encode or use host miRNAs to regulate their infection (5–7). Herpes simplex virus 1 (HSV-1) encodes miRNAs from 20 loci (miR-H1 to miR-H18 and miR-H26 to miR-H29), some of which are conserved in their genomic position and some of which are partially conserved in their sequence in the closely related herpes simplex virus 2 (HSV-2) (8–13). The genomic miRNA loci are scattered throughout the HSV-1 genome, but the most abundantly expressed miRNAs (miR-H1 to miR-H8) are located in close proximity or within the region encoding the latency-associated transcripts (LATs) (7). LATs are groups of long non-coding RNAs abundantly expressed during latent infection, whose function is quite enigmatic. Nonetheless, several functions have been ascribed to LATs, including inhibition of apoptosis, repression of productive gene expression, and viral chromatin organization (14–18). The expression of miRNAs encoded within the LATs is strongly dependent on the activity of the LAT promoter (miR-H2 to miR-H8), although other promoters may also contribute to their expression (19–21). These miRNAs follow the kinetics of LATs in establishment, maintenance, and reactivation from latency (19, 22, 23). It has been shown that miRNAs encoded upstream and in close proximity to the LAT promoter, miR-H1 and miR-H6, can negatively regulate the LAT transcript and LAT-associated miRNAs during productive infection in cell culture (24). Many of the LATs associated miRNAs are encoded antisense to key viral genes and are fully complementary to their transcripts, suggesting regulation of these genes (7). For example, miR-H2, miR-H7, and miR-H8 are encoded antisense to ICP0, a viral ubiquitin ligase that directs many proteins for degradation and has a function in inhibiting host defense mechanisms and promoting viral transcriptional activation (25, 26). miR-H3 and miR-H4 are encoded antisense to ICP34.5, also an inhibitor of intrinsic innate immunity (27). Nonetheless, viral mutants deficient for the expression of individual miRNAs usually exhibit little or no replication defects in cultured cells and retain wild-type or mild latency reactivation phenotype in animal models (24, 28–31). For example, the HSV-1 strain McKrae virus mutant with disrupted miR-H2 and intact ICP0 sequence exhibited increased neurovirulence and reactivation rate in a mouse model. In contrast, a similar KOS strain miR-H2 mutant showed wild-type characteristics (28, 31). Remarkably, in cultured cells, miR-H28 and miR-H29 have been shown to be exported by exosomes and that can limit virus transmission in recipient cells by inducing interferon production (12, 32). In addition to expressing its own miRNAs, HSV-1 deregulates the host miRNAome, and host miRNAs have been shown to contribute to efficient viral infection (33). For example, the neuronal miRNA miR-138 regulates the expression of ICP0 and multiple host targets to promote latent infection (34, 35). Nonetheless, exploring the exact roles of miRNAs in HSV-1 latency presents many challenges and has yet to be discovered.

Adenosine deaminase acting on RNA (ADAR) is a family of editing enzymes that catalyze adenosine-to-inosine (A-to-I) deamination in dsRNA (36). Inosine is read as guanosine by the translational machinery and viral RNA-dependent RNA polymerases, leading to recoding events (modified codons) and changes in viral genome (A-to-G transition). In addition, adenosine deamination can affect translational efficiency, change splicing, RNA structure and stability, and miRNA targeting (36). In humans, editing occurs at millions of sites and mostly in non-coding parts of the transcriptome (introns and untranslated regions) typically targeting dsRNA formed by pairing of two inverted copies of repetitive elements (37). The vast majority of A-to-I editing occurs within ~300 base pair (bp) long Alu repeats represented in more than a million copies. Vertebrates

have three ADAR genes: ADAR1, ADAR2, and ADAR3. ADAR1 and ADAR2 are enzymatically active, whereas ADAR3 has been shown to have a regulatory role (36). ADAR1 is expressed in two isoforms, a shorter isoform (ADAR1-p110) expressed from a constitutively active promoter and ADAR-p150, which is interferon inducible. The ADAR1-mediated editing has an essential role in preventing activation of the innate immune system and interferon overproduction by endogenous dsRNA (36).

Roles of ADAR proteins in virus replication, including herpesviruses, are not well understood, and there is evidence for anti-viral and pro-viral properties, depending on virus and host (38, 39). Editing of viral transcripts during productive or latent infection has been documented for some herpesviruses potentially affecting important biological processes (38, 40, 41). For example, editing of one of the most abundant transcripts found in KSHV latency, K12 (kaposin A) open reading frame, eliminates its transforming activity (42). More recently, Rajendren et al. found a number of additional edited transcripts, including KSHV-encoded miR-K12-4-3p (43). Editing of this miRNA impacts miRNA biogenesis and its target specificity. Moreover, ADAR1 function was found required for efficient KSHV lytic reactivation by modulating innate immunity signaling (44). Similarly, EBV-encoded miRNAs (miR-BART3, miR-BART6, miR-BART8, etc.) and recently identified non-coding lytic transcripts spanning the origin of replication (*oriP*) (*oriPtRs* and *oriPtLs*) are edited (45–47). Interestingly, editing of EBV miR-BART6 and miR-BART3 reduces their dicer targeting and affects viral latency. On the other hand, infection with human cytomegalovirus (HCMV) triggers increased ADAR1 levels and enhanced editing of host miR-376a, which in turn acquires the ability to downregulate the immunomodulatory molecule HLA-E and facilitate immune elimination of HCMV-infected cells (48).

In this study, we report a comprehensive analysis of HSV-1 miRNAs in latently infected human ganglia. We found evidence of specific A-to-I hyperediting of an HSV-1 miRNA, miR-H2. miR-H2 is hyperedited at nucleotide position N5 within the seed region, indicating a change in its specificity and targeting. We provided evidence that the edited miR-H2 has additional targets and that it can regulate ICP4, in addition to the previously determined target, ICP0.

RESULTS

miRNA sequencing

To analyze the expression of HSV-1 miRNAs in latently infected human neurons, we sequenced small RNAs extracted from sections of 10 latently infected human trigeminal ganglia (TGs) derived from 10 individuals (Table S1). Briefly, we extracted RNA and DNA from all samples and confirmed the presence of the HSV-1 genome prior to sequencing (Fig. S1). Small RNA libraries were generated using the NEBNext Multiplex Small RNA Library PreSet for Illumina and sequenced on the NextSeq 500 (Illumina). The obtained sequencing data sets were processed with sRNAtoolbox (49), an integrated collection of small RNA research tools, applying stringent parameters with exclusion of all bases with Phred score of <30.

We obtained between 2.6×10^7 and 1.5×10^7 high-quality sequencing reads per sample, of which between 2.6×10^6 and 9.5×10^6 represented miRNAs (Table 1). As expected, the vast majority of reads were human miRNAs (>99.8%), and only a small number of HSV-1 miRNAs were obtained (2–6,884 reads/sample) (Table 1). HSV-1 miRNAs detected in each individual sample did not correlate with the number of human miRNAs detected and ranged from 0.00003% to 0.17% (Table 1). These results could indicate differences in viral load, differences in processed sections of individual TG, and other factors.

The pattern of HSV-1 miRNA expression in human trigeminal ganglia

The expression of HSV-1 miRNAs in latently infected human ganglia has been comprehensively studied in only a few cases (10, 50), and in contrast to studies in cultured

TABLE 1 Number of sequencing reads representing human and HSV-1 miRNAs in human trigeminal ganglia

Sample	TG1	TG2	TG3	TG4	TG5	TG6	TG7	TG8	TG9	TG10
Raw reads ($\times 10^6$) ^a	22.8	18.7	15.8	18.9	21.2	15.0	14.8	18.5	26.1	18.9
Total reads ($\times 10^6$) ^b	15.9	13.2	10.9	13.0	13.9	10.5	10.3	13.3	18.7	13.7
Total miRNAs ($\times 10^6$) ^c	5.8	4.0	2.6	6.6	7.1	6.0	4.7	4.5	9.5	7.5
HSV-1 miRNAs ^d	5,468	4,043	4,453	6,884	4,405	512	1,140	2,264	4	2
HSV-1 miRNAs (%)	0.09421	0.10230	0.17071	0.10399	0.06190	0.00856	0.02436	0.05036	0.00004	0.00003

^aSequence reads generated from next-generation sequencing technologies, used for data analysis.

^bPre-processed reads that enter the analysis with removed adapters that satisfied parameters for length and quality of reads.

^cPre-processed reads that were assigned to the human and HSV-1 miRNAs from the miRBase database, together with hsv1-miR-H28 and hsv1-miR-H29 added to the database file.

^dPre-processed reads that were assigned only to the HSV-1 miRNAs from the miRBase database, together with hsv1-miR-H28 and hsv1-miR-H29 added to the database file.

cells and animal models, only a small subset of miRNAs has been detected (miR-H2 to miR-H8). Our study shows the expression of these miRNAs in all samples (Fig. 1) with a remarkably similar pattern. In two samples, we detected a low number of HSV-1 miRNAs, which could indicate a lower viral load or a variation within each tissue section. Based on the number of reads, the most abundant miRNA was miR-H4 followed by miR-H3, miR-H2, miR-H7, miR-H6, miR-H8, and miR-H5, with a range of 348 reads per million (RPM) for the most abundant and <1 RPM for the least abundant miRNA. The number of reads does not necessarily correspond to absolute quantification, as these numbers may depend heavily on the sequence of the miRNA and the sequencing protocol (51, 52). Nonetheless, these LAT-associated miRNAs define the pattern of HSV-1 miRNA in latently infected human trigeminal ganglia. In addition to these miRNAs, we detected miR-H1 and miR-H17 in TG4 and TG7, respectively (Fig. 1). miR-H1 was detected with only three reads (0.23 RPM) in sample TG4 but the reads fully matched the miR-H1 sequence deposited in miRbase, indicating a confident result. Since miR-H1 is abundantly expressed during productive infection (9), this could suggest a possible reactivation from latency in one of the samples. On the other hand, miR-H17 was detected with only a single read and the sequence was shorter (19 nt) and had a mutation compared to miRNA in miRBase, which may indicate false detection. It is important to note that the abundantly expressed HSV-1 miRNAs (miR-H2, miR-H3, miR-H4, miR-H7, except miR-H6) were readily detected with both strands of the duplex (5p and 3p) in ratios of 1:4 to 1:100, which is well above the average host miRNA strand bias (>1:1,000). These results suggest, at least for some HSV-1 miRNA, that both arms of the duplex may regulate specific targets. Indeed, this hypothesis is supported by the analysis of RNA-inducing silencing complex (RISC)-associated HSV-1 miRNAs in which both strands of the duplex were associated with the RISC [reference (30), and not shown].




FIG 1 The HSV-1 miRNA expression pattern in human trigeminal ganglia. RNA was extracted from latently infected trigeminal ganglia, and small RNA libraries were generated using the NEBNext multiplex small RNA Library Prep Set for Illumina and sequenced on the NextSeq 500 (Illumina). The obtained sequencing data sets were processed using sRNAtoolbox. The dots represent the number of RPM for the miRNAs detected in individual ganglia.

miR-H2 is hyperedited in latently infected human neurons

In our previous study, we identified particular sequence variants of HSV-1 miRNAs that could result from active post-transcriptional modifications by ADAR enzymes (50). To investigate this further, we analyzed the sequence variants of HSV-1 miRNAs in our data set. In total, we obtained approximately 29,000 reads representing HSV-1 miRNAs (ranging from 2 to 6,884/sample) under our threshold settings (i.e., maximum of two mismatches, allowing 5' and 3' fluctuations). Detailed analysis of the reads showed that 13.1% of all miRNAs had one or two nucleotide substitutions. This is comparable to the substitutions detected in the host miRNA data set (i.e., 11.5%). Remarkably, among all substitutions within viral miRNAs, we observed a very high frequency of A-to-G substitutions, which accounted for more than 50% of all nucleotide substitutions (Fig. 2A). Importantly, the frequency of nucleotide substitutions was comparable between host and viral miRNAs, and most types of substitutions were relatively rare. However, A-to-G substitutions were the most common substitution in both host and virus, and surprisingly, they occurred twice as frequently in virus as in host (Fig. 2B). It is possible that some of the detected substitutions are sequencing errors, but the observed high frequency of A-to-G substitutions indicated an active enzymatic process. Next, we




FIG 2 miR-H2 is hyperedited in latently infected human neurons. (A) Nucleotide substitution matrix of all HSV-1 miRNAs detected in eight hTGS ($n = 29,175$ miRNA reads). (B) Percentage of substitutions of host and viral miRNAs. The number of miRNAs reads from eight samples was analyzed using Student's t -test (P values indicate statistical differences; ** $P < 0.01$, *** $P < 0.001$). (C) Each panel represents the frequency of A-to-G substitutions for the miRNAs detected in each sample. (D) Percentage of the nucleotide substitutions per nucleotide in miRNA-H2-3p and miR-H4-3p marked in different colors. (E) Percentage of edited miR-H2-3p reads in human TGs. Each dot represents the percentage of indicated miRNA in individual TG samples. miR-H2-3p-e5 and miR-H2-3p-e9 indicate sequence editing at the nucleotide positions N5 and N9, respectively (number of all miR-H2-3p reads = 1,491). (F) Sequences of canonical hsv1-miR-H2-3p and edited isoforms. Edited A-to-G nucleotides are shown in bold at indicated positions N5 and N9. The seed sequence of miR-H2-3p is highlighted in gray. (G) The precursor of HSV-1 miR-H2 was amplified using 50 ng of DNA extracted from three latently infected human ganglia (TG2, TG6, and TG10), with the cloned HSV-1 genome strain KOS (BAC) and HEK293 cells productively infected with HSV-1 strain KOS (HEK293) using the primers FP: 5'-GCCCGCCCCCCCCGAG-3' and RP: 5'-ACACGGCGCGGUCGCG-3', and directly sequenced with FP primer. The red arrows point to the nucleotides at positions N5 and N9 of miR-H2-3p.

carefully analyzed the A-to-G substitutions for each miRNA and found that the frequency of A-to-G substitutions for most viral miRNAs was very low, similar to the baseline level (<1%) (Fig. 2C). On the other hand, miR-H2-3p was in each sample represented with 35–48% reads having A-to-G substitutions and accounted for nearly 80% of all A-to-G substitutions in HSV-1 miRNAs (Fig. 2C and D). We observed the vast majority of A-to-G substitutions at the nucleotide positions N5 (miR-H2-3p-e5) (Fig. 2D). In addition, we detected a lower level of editing at the N9 nucleotide position (<10%). The pattern of N5 and N9 nucleotide substitutions was conserved in all latently infected TG with detectable miR-H2 (Fig. 2E). Other types of substitutions were at negligible levels (Fig. 2D).

This result was quite surprising, as HSV-1 miRNAs are considered highly conserved. Indeed, comparison of the pre-miR-H2 sequence of laboratory and clinical strains showed strict conservation (not shown). Moreover, the reproducible pattern of the miR-H2 editing in all analyzed samples strongly indicates a specific modification. However, to exclude the possibility that the sequence variants were due to heterogeneous infection, i.e., different virus strains carrying nucleotide variations in the miR-H2 gene, we sequenced PCR amplicons generated on the DNA template of three TGs analyzed (TG2, TG6, and TG10). We also sequenced amplicons obtained from the cloned genome of the HSV-1 strain KOS and DNA extracted from cells infected with HSV-1 in culture, which served as a monoclonal control. In the case of heterogeneous infection, one would expect overlapping sequencing signals for nucleotides A and G. In contrast, we found no evidence of variation at the indicated editing sites in any of the samples (Fig. 2F and G). Overall, our results suggest that miR-H2 variants arise by post-transcriptional sequence-specific editing in latently infected neurons, which is similar to the signature of A-to-I deamination by ADAR proteins (53). Curiously, we also observed other nucleotide substitutions in viral miRNAs, such as T-to-C (17% overall) or C-to-T (5.7%) (Fig. 2A), which were distributed across all detected viral miRNAs with low frequency for individual miRNAs (not shown) and were therefore not analyzed further. Figure 2D shows the substitutions per nucleotide in miR-H4, an example of a highly expressed viral miRNA that, unlike miR-H2, shows no signs of hyperediting.

ADAR1 and ADAR2, the two enzymatically active members of the ADAR protein family, are known to be ubiquitously expressed in various tissues, including the brain (54). To confirm that these genes are expressed in the tissue where we detected potential post-transcriptional editing, we analyzed RNA and proteins extracted from human TG tissue. Using reverse transcription quantitative real-time PCR (RT-qPCR), we confirmed the expression of ADAR1 and ADAR2 in human TGs (Fig. 3). On the other hand, we detected higher levels of ADAR1 p110 protein compared with the interferon-inducible p150 form, which could be detected only with an isoform-specific antibody (Fig. 3). The expression of ADAR2 was below our detection limit, consistent with relatively low levels of the ADAR transcript. In addition, we detected nuclear and moderate cytoplasmic staining of neuronal cells with immunohistochemistry and two different ADAR1 antibodies. ADAR1 expression was also observed in small surrounding cells that may correspond morphologically to satellite glial cells (two middle panels). ADAR2, on the other hand, was observed almost exclusively in nuclei and was also present in surrounding satellite cells (lower panel). Immunohistochemical signals were not detected in stromal connective tissue. Taken together, these results suggest that ADAR proteins might process miR-H2 in latently infected human TG.

Low levels of HSV-1 miRNA editing during productive infection in culture

We demonstrated that sequence-specific hyperediting of miR-H2 occurs during long-lasting latency in humans, which might have important implications for understanding the molecular mechanisms regulating latency. We next asked whether editing of miR-H2 could also be observed during productive infection in cultured cells, which would strongly suggest sequence-specific deamination. Importantly, under such experimental conditions, the infection can be considered monoclonal with respect to sequence variations. To address these questions, we reanalyzed our previous sequencing




FIG 3 Expression of ADAR1 and ADAR2 in human trigeminal ganglia. (A) Immunohistochemical analysis of ADAR1 and ADAR2 expressions in human TGs. Sections of paraffine-embedded TG tissue (4 μ M) were stained with rabbit monoclonal α -ADAR1 IgG (Cell Signaling Technology), mouse monoclonal α -ADAR1 IgG (Santa Cruz Biotech), and mouse monoclonal α -ADAR2 IgG (Santa Cruz Biotech) and visualized using peroxidase-labeled polymer linked to goat α -rabbit and α -mouse immunoglobulins and 3,3'-diaminobenzidine. Slides were counterstained with hematoxylin and analyzed by an Olympus BX51 microscope equipped with a DP50 camera and Cell^f software (Olympus, Japan). The magnification is indicated in each panel (\times 100 or \times 600). HE, ADAR1, and ADAR2 staining is shown in neurons; (B) RNA was extracted from human trigeminal ganglia (indicated TG samples TG1–TG5), and ADAR1 and ADAR2 transcripts were amplified using RT-PCR and specific primers. PCR products were visualized using by agarose gel electrophoresis. RTneg-control represents the samples processed without the reverse transcriptase. (C) Proteins were isolated from sections of two randomly selected human trigeminal ganglia (TG7 and TG9) with RIPA buffer [150-mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), with protease inhibitors (cOmplete, Roche, Basel, Switzerland)] and analyzed by Western blot. ADAR1 was detected with the α -ADAR1 antibody (Santa Cruz Biotech) (upper panel) or the ADAR1 p150 antibody (Cell Signaling) (middle panel).

of smRNAs from productively infected human foreskin fibroblast (HFF) with the HSV-1 strain KOS at a multiplicity of infection (MOI) of 5 (ref) at 8 and 18 h post-infection (h.p.i.). As expected, we detected almost all previously reported HSV-1 miRNAs (except miR-H3, miR-H18, and miR-H27), which differed significantly in abundance (Fig. 4A). HSV-1 miRNAs were represented with 243 714 reads and 8.71% had one or two nucleotide substitutions, consistent with the basal frequency of substitutions observed in human latency samples. T-to-C (25.0%) and C-to-T (29.3%) nucleotide substitutions were the most common (Fig. 4B), but these were all randomly scattered across all detected miRNAs (not shown). Although it is possible that some of these represent sequencing errors, it cannot be excluded that C-to-T nucleotide substitutions are the result of random APOBEC3 activity.

In addition, we detected high levels of A-to-G substitutions (12.4%), which were significantly higher than most of the other substitutions, but still the phenomenon of




FIG 4 Low levels of A-to-I editing during productive HSV-1 infection. (A) HFF cells were infected with HSV-1 strain KOS at an MOI of 5 and smRNAs were analyzed by sequencing. The expression of miRNAs is shown as RPM. The experiment was performed in four replicates for each time point. (B) Substitution matrix of all detected HSV-1 miRNAs ($N = 243\,714$ HSV-1 miRNA reads). (C) Each field represents the frequency of A-to-G substitutions for the miRNAs listed below in each sample. (D) Percentage of edited miR-H2-3p reads. miR-H2-3p-e5 and miR-H2-3p-e9 indicate sequence editing at the nucleotide positions N5 and N9, respectively (number of all miR-H2-3p reads = 273).

hyperediting was less pronounced than in latently infected human ganglia (Fig. 4B). In contrast to latency in humans, miR-H2 editing was not highly overrepresented (14% of all A-to-G editing), and it was slightly above the frequency of A-to-G substitutions in most detected miRNAs. However, we observed two important correlations with the latent samples. First, miR-H2 editing showed a slight but reproducible increase from early (8 h) to late (18 h) times post-infection, i.e., from 2.7% to 5.9% (Fig. 4D). Second, miR-H2 editing occurred at the same nucleotides (N5 and N9) and in similar ratios between these two substitutions as observed for latency (Fig. 4D). In addition, we observed higher frequency of A-to-G substitutions for miR-H11, miR-H12, and miR-H13 (Fig. 4C), miRNAs that arise from transcripts spanning *oriS* and *oriL* regions (9). Although we cannot

determine whether these substitutions represent true editing events, due to the very small number of reads, it is possible that palindromic sequences of oriS and oriL could be genuine substrates for ADAR binding and editing.

miR-H2 is edited in latently infected mouse trigeminal ganglia

To investigate whether the representative animal model recapitulates the miRNA editing profile in humans, we analyzed miRNAs from acutely and latently infected mouse TGs [3, 14, and 30 days post-infection (d.p.i.)]. As expected, we found an increasing number of miRNAs and reads for each miRNA detected with increasing time post-infection, consistent with the previously determined kinetics of virus replication and establishment of latency in the mouse model after corneal scarification (Fig. 5A). The pattern of miRNAs and nucleotide substitutions within miRNAs resembled the pattern found in human tissue. A-to-G substitutions accounted for the majority of nucleotide substitutions (32%) (Fig. 5B), but were not as pronounced as in human tissues. Nevertheless, miR-H2 changes represented the vast majority of these substitutions (72% and 90% at D14 and D30, respectively), and the pattern was similar to that found in humans (i.e., miR-H2-e5 10.7% and miR-H2-e9 3.5% at D30) (Fig. 5C and D). These results indicate that HSV-1 latency in mice, at least in terms of miRNA expression and the ability of mouse proteins ADAR to edit miR-H2, largely recapitulates human latency.

miR-H2 expressed by HSV-2 does not show evidence of hyperediting

We were also interested in whether hsv2-miR-H2-3p encoded by HSV-2, the sequence and position homolog of hsv1-miR-H2-3p, also shows evidence of editing in productive and latent infections. We use our previously described data sets (9) to reanalyze them and find evidence of hyperediting. Briefly, for analysis of productive infection, HEK-293 cells were infected with the HSV-2 strain 186ΔKpn, a thymidine kinase-negative viral mutant that can establish latency in TGs without lethality to mice, with an MOI of 1, and samples for sequencing were collected 18 h.p.i. For analysis of latency, mice were infected intranasally and TGs harvested 30 d.p.i. As expected, we detected a large number of miRNAs during productive infection (Fig. 6A) and only a limited number of miRNAs during latency (hsv2-miR-H2, hsv2-miR-H7, and hsv2-miR-H24). Similar to productive infection of HSV-1, A-to-G substitutions accounted for approximately 12% and 23% of all substitutions in productive and latent infection, respectively (Fig. 6B and C). hsv2-miR-H2-3p was detected with 40 reads, but we were unable to detect any read with the A-to-G substitution. We are aware that this is a relatively small number of reads, but we were still surprised that we did not find any read with A-to-G substitutions (Fig. 6D), as pre-miRNAs are relatively conserved between these two viruses (Fig. 6E). Interestingly and similar to HSV-1, miRNA arising from a transcript spanning the oriL palindrome, hsv2-miR-H11, shows a relatively high frequency of A-to-G substitutions (16.2%; blue color, Fig. 6D) in productive infection. Overall, the most abundant substitutions in the HSV-2 experiment were G-to-A (Fig. 6B) for the productive infection and G-to-T for the latent sample (Fig. 6C). However, we did not observe confident higher representation of specific substitutions for any of miRNAs (i.e., all below 1%) but rather scattered across all detected reads.

Editing of miR-H2 extends its targeting potential

We show evidence of miRNA editing in latently infected human ganglia and in latently infected mice. Moreover, editing can also be observed during productive infection in culture, the system in which miRNA plays a minor role in efficient viral replication. Overall, it is expected that it will be very difficult to determine the biological significance of these events using current experimental models. miR-H2 deletion mutants, e.g., show little phenotype in mice (28). Nonetheless, we wanted to investigate the potential of edited miRNAs to regulate additional viral or host targets.

First, we asked whether the edited form is efficiently associated with the RISC, which should indicate their inhibitory potential. To this end, we infected HFF cells in triplicate at




FIG 5 A-to-I hyperediting during latent HSV-1 infection in mice. (A) RNA was extracted from mouse trigeminal ganglia at 3 ($N = 1$), 14 ($N = 3$), and 30 ($N = 2$) d.p.i., and small RNA libraries were generated using the NEBNext Multiplex Small RNA Library Prep Set for Illumina and sequenced on the NextSeq 500 (Illumina). The obtained sequencing data sets were processed using sRNAToolbox. The bars represent the number of reads per million for the miRNAs detected in individual mouse ganglia marked using different colors. (B) Substitution matrix of all detected HSV-1 miRNAs ($N = 3,858$ HSV-1 miRNA reads). (C) Each field represents the frequency of A-to-G substitutions for the miRNAs listed below in each sample. (D) Percentage of edited miR-H2-3p reads. miR-H2-3p-e5 and miR-H2-3p-e9 indicate sequence editing at the nucleotide positions N5 and N9, respectively (number of reads = 149).

an MOI of 10 and extracted 12 h.p.i. RNAs from whole cell lysates or immunoprecipitated Ago2, the major component of the RNA-inducing silencing complex. We postulated that a consistent ratio of canonical to edited miRNA in Ago2 pull-down and total miRNA would indicate efficient loading of edited miRNA into RISC (55). Indeed, the percentage of edited miRNA (miR-H2-3p-e5) in the total miRNA samples was 8.09%, while it was 10.23% in the Ago2 pull-down, indicating an efficient association with RISC (Table 2).

Next, we predicted the host and viral targets of these miRNAs. Not surprisingly, the targets of miR-H2 and miR-H2-e5 overlapped only slightly using two common prediction algorithms, TargetScan and miRDB (Fig. 7A; Table S4). These results suggest that editing significantly increases the potential of miR-H2 to regulate host genes. Of note, miR-H2-e9 was not included in the analysis because the host target prediction algorithms are largely based on the seed sequence, and miR-H2-e9 has the same sequence as miR-H2. However, this does not exclude a possibility that miR-H2-e9 regulated different transcripts.

TABLE 2 Edited miR-H2 is associated with Ago2^b

	RC miR-H2-3p-e5	RC miR-H2-3p	Percentage of miR-H2-3p-e5 (%)
Total ^a	351	4,338	8.09
IP-Ago ^a	309	3,020	10.23
IP-GFP ^a	25	211	11.85

^aThe number of reads were adjusted according to the size of the sequenced sample: IP 9/10 and total 1/10 of the sample.

^bRC, read count.




FIG 6 No evidence for A-to-I hyperediting in productive or latent HSV-2 infection. (A) HEK293 cells were infected with HSV-2 thymidine kinase-negative mutant of HSV-2 strain 186syn+ (HSV-2) at an MOI of 1 for productive infection ($N = 1$), and for the latent infection, 7-week-old male CD-1 mice (Harlan) were infected intranasally with 1×10^6 PFU of HSV-2; mTGs were extracted 30 d.p.i., and smRNAs were analyzed by sequencing ($N = 1$). The expression of miRNAs is shown as RPM; (B) Substitution matrix of all HSV-1 miRNAs detected in HEK293 samples productively infected with HSV-2 ($N = 1,705$ HSV-2 miRNA reads). (C) Substitution matrix of all HSV-1 miRNAs detected in mTG samples 30 d.p.i. latently infected with HSV-2 ($N = 284$ HSV-2 miRNA reads). (D) Each field represents the frequency of A-to-G substitutions for the miRNAs listed below in each sample. (E) Sequence comparison between pre-mir-H2 of HSV-1 strain 17 and HSV-2 strain HG52. The miR-H2-3p is shown in the red frame; and the seed sequence is shown in red.

Regarding potential viral targets, miR-H2 is fully complementary to the ICP0 transcript and likely represents the main target of miR-H2-3p (8). We used the Bowtie alignment tool (58) to predict potential viral targets of miR-H2-3p and its edited forms. We identified 17 potential binding sites for miR-H2-3p, including the previously identified ICP0. Surprisingly, one nucleotide substitution within the seed region of miR-H2 (i.e., miR-H2-e5) results in a dramatic increase in predicted targets (i.e., 79 loci), which include ICP0, ICP4, and a large number of other productive infection gene transcripts (Table S2). Although the functional characterization of miR-H2-e5 is experimentally challenging and beyond the scope of this manuscript, we carefully analyzed the potential binding sites for miR-H2 and miR-H2-e5 within the ICP0 and ICP4 transcripts using RNAhybrid and allowing G-U base pairing. Similar to Bowtie prediction, editing miR-H2 increased the number of potential target sites in both transcripts (Table S3). Indeed, the canonical




FIG 7 Targeting potential of miR-H2 is expanded by editing of the seed sequence. Predicted human targets of canonical (purple) miR-H2-3p and edited miR-H2-3p (orange) using (A) TargetScan (56) and (B) miRDB (57).

miR-H2 has only one fully matched seed-target site in the ICP0 and ICP4 transcripts, whereas editing at position N5 results in four and seven potential seed matches in the ICP0 and ICP4 transcripts, respectively.

To preliminary test whether miR-H2-3p edited at positions 5 and/or 9 has the potential to regulate the expression of ICP0 or ICP4, we performed co-transfection experiments. Briefly, we co-transfected HEK293 cells with a wild-type ICP0 or ICP4 expression plasmid together with a pEGFP plasmid (an indicator of non-selective targeting) and microRNA mimics including canonical miR-H2-3p, miR-H2-3p with scrambled seed sequence (miR-H2-3p-mut), negative control mimic (scrambled sequence), edited miR-H2-3p at position 5 and/or 9, or both (miR-H2-3p-e5, miR-H2-3p-e9, miR-H2-3p-e5-e9; Fig. 8). As shown in Fig. 8, canonical miR-H2-3p significantly decreased ICP0 levels and to laser extent ICP4 levels. Downregulation of ICP4 was expected based on one seed match within the ICP4 transcript (Table S3). On the other hand, miR-H2-e5 strongly decreased the levels of both ICP0 and ICP4 (Fig. 8B through E),




FIG 8 miR-H2-3p-e5 can downregulate ICP0 and ICP4. (A) Sequences of miRNA mimics. Single-stranded mimics with modified 2'OME corresponding to the canonical or edited sequence were used: canonical miR-H2-3p (miR-H2-3p-wt), a mutated seed sequence of the miR-H2-3p marked bold (miR-H2-3p-mut), edited miR-H2-3p on positions 5 and 9 or both (miR-H2-3p-e5, miR-H2-3p-e9, and miR-H2-3p-e5-e9); inosines are marked bold. (B) Proteins extracted from HEK293 cells transfected with plasmid expressing GFP (pEGFP-N1) and ICP0 (pRS-1-ICP0), and co-transfected with miRNA mimics indicated above the panel were analyzed by Western blot. (C) Quantification of ICP0 protein levels from three different experiments (panel B and Supplemental Info, $N = 3$) using ImageJ and normalized to actin. (D) HEK293 cells were transfected plasmids expressing enhanced green fluorescent protein (EGFP) (pEGFP-N1) and ICP4 (pcDNA-1-ICP4), and co-transfected with miRNA mimics indicated above the panel. (E) Quantification of ICP4 protein levels from three different experiments (panel D and Supplemental Info, $N = 3$) using ImageJ and normalized to actin. Results were analyzed using Student's t -test (P values indicate statistical differences; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$).

whereas miR-H2-e9 had a slight effect on ICPO only. Interestingly, miR-H2 edited at both sites and miR-H2-e5-e9 showed no effect on either transcript. The levels of these proteins were not affected by miR-H2-3p-mut and negative control. These initial results, albeit in an overexpression system, suggest that miR-H2 may play a broader role in repressing early genes during latency.

DISCUSSION

Our data show that miR-H2 encoded by HSV-1 is post-transcriptionally edited in latently infected human neurons, leading to an expansion of potential host and viral targets that may play a role in regulating latency. The observed A-to-G substitutions are the signature of the ADAR proteins that catalyze the deamination of pri-miRNA/pre-miRNAs. Because of relatively small number of latently infected neurons, HSV-1 miRNAs are present at very low levels in human tissues, so our analysis is largely based on next-generation sequencing, which can provide sufficient depth and resolution.

The miRNA pattern of HSV-1 latency

Our analysis of 10 latently infected human ganglia reveals remarkably similar patterns of HSV-1-encoded miRNAs in all samples, largely confirming the results of previous studies (10, 50). These include miR-H2 to miR-H8, which likely represent the HSV-1 miRNA latency pattern. We cannot rule out the possibility that with increasing depth (higher number of reads) other miRNAs are not found but would certainly be underrepresented. Similar to humans, latently infected ganglia from mice have the same miRNA expression pattern. It is important to note that standard latent infection models in mice are based on 30-day infection, which is far less than latency studied in humans. Also, latency in mice is established after massive productive infection within TG, which is not the case in humans. Therefore, there is increased potential for residues of productive infection transcripts to exist at 30-d.p.i. mice compared to the human samples, including appearance of some miRNA. The exact function of these miRNAs is still quite enigmatic, mainly because studies on HSV-1 miRNAs during the latent phase of infection have multiple challenges and drawbacks. An important advance in understanding the role of HSV-1 miRNAs has been made using viral mutants lacking single miRNAs, but the observed phenotypes are generally mild (24, 28–31, 59). This is to be expected because miRNAs likely regulate the robustness of the system (i.e., sensitive on/off switches) rather than enabling latency or reactivation. Interestingly, in HSV-1, miRNAs present in latency have both arms of the miRNA duplex, suggesting that viruses use the miRNA machinery particularly efficiently.

Editing of miR-H2

Our study provides several lines of evidence that miR-H2 is hyperedited during latency, further increasing its targeting potential. First, the sequencing data were analyzed under stringent cutoff values, resulting in highly reliable sequence information. Second, sequencing of DNA in all samples analyzed revealed no evidence of heterogeneity within the precursor of the HSV-1 miR-H2 (pre-miR-H2) locus, suggesting that miR-H2 heterogeneity is due to post-transcriptional modifications of its transcripts. Third, the pattern of miR-H2 expression (ratio of edited to unedited forms) was remarkably consistent in all samples. It is highly unlikely that all patients carry similar genomic variants. Fourth, evidence from sequencing of numerous viral genomes suggests that the miR-H2 locus is highly conserved. Fifth, we found the same editing pattern (i.e., miR-H2 positions N5 and N9) in productively infected cells in culture, albeit at lower frequency, and in the mouse model, suggesting a specific editing process. We believe that the lower frequency of miR-H2 editing in productive infection is due to the ADAR proteins being saturated with the overwhelming viral transcript. This is in contrast to the latency phase, where fewer transcripts are present and can be efficiently edited.

Interestingly, we found no evidence of site-specific hyperediting for the encoded HSV-2 homolog; however, in the context of limitations this study, we cannot rule out

the possibility that hsv2-miR-H2 is edited, especially as mice were infected with a TK-null virus, which would limit viral replication in the ganglia prior to latent establishment. In the HSV-2 data set, we found a relatively small number of reads representing miR-H2, and unfortunately, we were unable to obtain human tissues latently infected with HSV-2.

How the ADAR1 and ADAR2 editors select their targets is not clear, but the length and structure of the dsRNA (bulges, loops, and mismatches) play an important role. The precursors of the pre-miRNAs of HSV-1 and HSV-2 are very similar (9), and the adenosine targeted by editing at position N5 is conserved, and we found no clear evidence or motifs for differential specificity of editing. For the pre-miR-H2, the optimal secondary structure was predicted to have a slightly higher minimum free energy (-37.50 kcal/mol), higher than all other commonly expressed miRNAs and higher than HSV-2 miR-H2 (-40.40 kcal/mol). Editing at the N5 position slightly lowers the folding energy. Nevertheless, detailed studies on host miRNAs and viral miRNAs are needed to establish such a correlation. In addition to the A-to-G substitutions, we observed relatively many other substitutions in our analysis. Some of these could be due to technical sequencing errors (51), while others could be active processes. The APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like) family of proteins binds to both RNA and single-stranded DNA and may be responsible for some of the C-to-T substitutions (60), but investigating this is beyond the scope of this study.

Possible roles of editing

The main question is whether editing of miR-H2 has biologically relevant functions. Our results indicate that the edited miRNA is loaded into the RISC as efficiently as the canonical sequence, suggesting functional properties. Furthermore, we show that editing miR-H2, similar to other edited miRNAs, could increase its targeting potential. Indeed, using co-transfection assays, we demonstrated that canonical miR-H2-3p and miR-H2-3p-e5 can target ICP0 and ICP4 transcripts and limit their protein levels. Moreover, miR-H2-3p-e9 was effective against ICP0. These results could be explained by the proportional number of predicted miRNA binding sites within these transcripts (Table S3). However, an miRNA in which both sites were edited was not effective against either transcript, and the prediction would indicate binding. At this stage, we cannot explain the discrepancy between the computational predictions and the experimental results. Clearly, more sophisticated techniques are needed to determine the exact binding sites and target transcripts and to investigate the functions of these miRNAs. Nonetheless, it is important to note that viruses lacking miR-H2 expression, which includes both canonical and edited miRNA, exhibit a mild phenotype in latency models (28, 31, 34), suggesting that editing may at best contribute to the observed phenotype. Current latency models rely on relatively harsh experimental conditions, including viral reactivation in explanted tissues, which may not provide the resolution necessary to study miRNA-regulated processes. However, recently developed models in primary neurons of latency establishment and reactivation, where reactivation is induced on intact neurons, may in the future prove useful for investigating the function of ADAR in HSV neuronal infection (61). One potential caveat, however, is that studying the biological role of editing is challenging because it is challenging to generate ADAR1 KO in most cells. In addition to the evidence that editing affects targeting properties, it is also possible that editing of the miR-H2 precursor affects its biogenesis, as shown for EBV- and KSHV-encoded and edited miRNAs (43, 45, 46). ADAR1 was shown to directly interact with DICER and affect miRNA processing, maturation, RISC loading, and silencing of target RNAs, all of which remain to be investigated. To our surprise, we did not find evidence of HSV-2 miR-H2 editing, nor in infected cells in culture, nor in latently infected trigeminal ganglia. At this stage, because of the relatively small number of reads, we cannot rule out the possibility that hsv2-miR-H2 is edited. We can speculate that editing may be the molecular mechanism that determines some biological differences between HSV-1 and HSV-2. Therefore, it is critical to sequence relevant human samples, such as the dorsal root ganglia, to determine the status of HSV-2 miRNAs during latency. In

addition, our study suggests that other non-coding RNAs, i.e., LAT intron, can be edited during latency, which may explain some of the peculiar properties of this molecule. For example, editing the LAT intron could prevent this abundantly expressed molecule from being recognized as non-self, which would lead to apoptosis (62). Editing could also affect its expression and stability or be essential for its interactome (63), and yet there is still much to learn about the importance of post-transcriptional editing in herpesvirus infection.

MATERIALS AND METHODS

Trigeminal ganglia were removed from 10 subjects within 24 h after death (Table S1). At the time of death, patients had no symptoms of HSV-1 infection. TG specimens were immediately frozen and stored at -80°C until further processing.

Cells, viruses, infection, and plasmids

Human Embryonic Kidney (HEK293, CRL-1573) and human foreskin fibroblast (generous gift of S. Jonjić, Faculty of Medicine, University of Rijeka) were grown in Dulbecco's Modified Eagle Medium (PAN-Biotech) supplemented with 10% fetal bovine serum (PAN-Biotech), penicillin/streptomycin $100\ \mu\text{g}/\mu\text{L}$, 2-mM L-glutamine (Capricorn), and 1-mM sodium pyruvate (Capricorn), under standard conditions in humidified incubator at 37°C and in the presence of 5% CO_2 . Wild-type HSV-1 strain KOS (kindly provided by Professor Donald M. Coen and David Knipe, Harvard Medical School, Boston, USA) was prepared in Vero cells and stored at -80°C as previously described (64). For productive infection, cells were seeded on the dish or plate the day before the experiment. After 24 h, cells were infected with specified viruses from a viral stock, with indicated multiplicity of infection or mock infected (uninfected). The medium in all samples was replaced with fresh growth medium 1 h after infection. Samples were collected at specified hours post infection. For latent infection, 6-week-old female CD-1 mice (Charles River) were anesthetized by intraperitoneal injection of ketamine hydrochloride (80 mg/kg of body weight) and xylazine hydrochloride (10 mg/kg) and inoculated with 1.5×10^6 PFU/eye of KOS strain HSV-1 (in a $5\text{-}\mu\text{L}$ volume) onto scarified corneas, as described previously (65). Mice were housed in accordance with institutional and National Institutes of Health guidelines on the care and use of animals in research, and all procedures were approved by the Institutional Animal Care and Use Committee of the University of Virginia. Trigeminal ganglia were harvested 3, 14, and 30 d.p.i. and immediately snap frozen in liquid nitrogen. For RNA extraction, lysis was carried out by addition of RNA lysis buffer (Zymo) and homogenization for 60 s using the BeadBug microtube homogenizer. RNA was isolated from the homogenized mixture using the *Quick-RNA* miniprep kit (Zymo).

The ICP0-WT plasmid (pRS-1) was a generous gift of Rozanne Sandri-Goldin (University of California). This plasmid includes the entire *ICP0* gene, with its promoter, cloned into pUC-18 (35, 66). pcDNA-1-ICP4 contains the entire *ICP4* gene (67). pEGFP-N1 was obtained from Clontech-Takara.

Nucleic acid extraction

Trigeminal ganglia were thawed and small sections homogenized and dissolved in TRIreagent (Ambion). DNA and RNA were extracted from the same sample according to the manufacturer's instructions. Briefly, chloroform was added in TRIreagent to separate the RNA in the aqueous phase and precipitated with isopropanol. After washing with 70% ethanol, the precipitate was resuspended in nuclease free water and treated with DNase for 30 min. The remaining sample from which the aqueous phase was removed was used for DNA precipitation with absolute ethanol. HEK293T and HFF samples were homogenized in TRIReagent solution (Ambion) on ice, and total RNA was extracted according to the manufacturer's protocol. DNA and RNA concentration and quality were measured using UV/VIS spectrophotometer (BioDrop μLITE , UK).

Massive parallel sequencing

Small RNA sequencing libraries were prepared using NEBNext Multiplex Small RNA Library Prep Set for Illumina using standard protocol according to the manufacturer's instructions. Libraries were size selected by using AMPure XP beads to selectively bind DNA fragments 100 bp and larger to paramagnetic beads. Samples were sequenced on NextSeq 550 NGS platform (Illumina) using single-end sequencing mode with total of 36 cycles. RNAs extracted from immunoprecipitated complexes using Ago2 and GFP antibody were used to generate small RNA sequencing libraries using TruSeq Small RNA Kit (Illumina), according to the manufacturer's instructions. cDNA libraries were size selected using 10% PAGE (BioRad), and species from 15 to 30 nt were isolated. cDNA libraries were then sequenced by single-read sequencing (50 nt) in Illumina HiSeq 2,500 sequencer.

Data analysis

For quality control check on raw sequences, we used FastQC. The sequencing data were analyzed using sRNAbench (Computational Epigenomics Lab, Evolutionary Genomics and Bioinformatics Group, Department of Genetics, Institute of Biotechnology, University of Granada, Spain) (49, 68, 69). Briefly, 3' flanking sequencing adapter sequence was removed from all the reads, and reads were aligned against the human reference genome (Genome Reference Consortium Human Build 38 patch release 13) and HSV-1 strain 17 (NC_001806.2) or HSV-1 KOS strain (JQ673480.1). Reads smaller than 18 were excluded, as were the reads with a sequencing quality score lower than 30, to obtain high-quality reads. To assign the reads to known miRNAs, reads were aligned against known miRNAs from the miRBase sequence database (release 22), human and HSV-1, while published HSV-1 miRNAs not represented within the miRBase, hsv1-miR-H28, and hsv1-miR-H29 were added to the database file based on the published sequence. We allowed for two nucleotide mismatches in the first 19 nucleotides mapped but also accepted all sequences that started at most three nucleotides upstream and ended at most five nucleotides downstream of the reference sequence.

For the prediction of the host targets, prediction tools such as TargetScanHuman v.5.2 Custom (70) and miRDB (57) were used to search for the presence of sites that match the seed region of miRNA, nucleotides from 2 to 8, and for the viral targets, we also searched for the presence of sites complementary to the seed region of miRNA using Bowtie alignment tool (58). In addition, we used RNAhybrid (71), applying standard settings to visualize 10 miRNA-target bindings in the ICP0 and ICP4 region.

Immunohistochemistry

Immunohistochemical staining of ADAR proteins was conducted using DAKO EnVision + System, Peroxidase [3,3'-diaminobenzidine (DAB) kit (DAKO Cytomation, Santa Clara, CA, USA) on 4- μ M-thick serial sections of paraffin-embedded TG tissues. Briefly, after deparaffinization and rehydration, tissues underwent heat-mediated epitope retrieval by microwave heating in a 10-mM citrate buffer, pH 6.0. Having subsequently been treated with blocking solution, slides were incubated with rabbit monoclonal α -ADAR1 IgG (Cell Signaling Technology; diluted 1:100 in 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), mouse monoclonal α -ADAR1 IgG (Santa Cruz Biotech; diluted 1:100 in 1% BSA in PBS) and mouse monoclonal α -ADAR2 IgG (Santa Cruz Biotech; diluted 1:100 in 1% BSA in PBS) over 12 h in a humid chamber at 4°C. As a secondary antibody, a peroxidase-labeled polymer linked to goat α -rabbit and α -mouse immunoglobulins was applied for 30 min at room temperature. Immunoreactions were visualized by DAB, and slides were counterstained with hematoxylin. After being dehydrated, slides were mounted with Entellan (Sigma-Aldrich, Hamburg, Germany) and analyzed by an Olympus BX51 microscope equipped with a DP50 camera and Cell^f software (Olympus, Japan). The specificity of antibody binding was verified performing negative controls by substitution of ADARs antibodies with isotype-matched control antibodies applied in the same conditions. Negative control slides showed no immunohistochemical signals.

Transfection

Single-stranded RNAs with modified 2'Ome designed to mimic canonical miR-H2-3p (miR-H2-3p-wt—5'-CCUGAGCCAGGGACGAGUGCGACU-3'), mutated seed sequence of the miR-H2-3p (miR-H2-3p-mut—5'-CGCCAUCGAGGGACGAGUGCGACU-3'), edited miR-H2-3p on positions 5 and/or 9 or both (miR-H2-3p-e5—5'-CCUGIGCCAGGGACGAGUGCGACU-3', miR-H2-3p-e9—5'-CCUGAGCCIGGGACGAGUGCGACU-3', miR-H2-3p-e5-e9—5'-CCUGIGCCIGGGACGAGUGCGACU-3'), and negative control mimic were ordered from GenePharma. Plasmid (pRS-1-ICP0/pcDNA-1-ICP4/pEGFP-N1) and miRNA mimic co-transfections were performed in HEK293T cells using Lipofectamine 3000 according to the manufacturer's instructions without the addition of the P3000 reagent. Briefly, cells were seeded in a 24-well plate to be 70% confluent for the transfection. Cells were co-transfected with 70 ng per well of ICP0 expression plasmid or 50 ng per well of the ICP4 expression plasmid, 30 ng per well of the pEGFP-N1 expression plasmid, and with 30 nM of the mimic or negative control, using 1 μ L of Lipofectamine 3,000 per well. After 24 h, samples were extracted for Western blot analysis.

Western blot

To extract the proteins, cells were collected at indicated timepoints and lysed in RIPA buffer [150-mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), with protease inhibitors (cOmplete, Roche, Basel, Switzerland)], mixed with 2 \times Laemmli buffer with β -mercaptoethanol (Santa Cruz Biotech, Dallas, TX, USA) and denatured for 6 min at 95°C. Proteins were separated in 10% SDS-PAGE gels and transferred onto a nitrocellulose membrane (Santa Cruz Biotech). Membranes were blocked in 5% (wt/vol) non-fat dry milk in 1 \times Tris-buffered saline (TBS) for 30 min at room temperature followed by the incubation at 4°C with gentle rotation overnight with the primary antibodies with specified dilutions: α -actin (MilliporeSigma, Burlington, MA, USA)—1:10,000; α -ICP0 (Abcam, Cambridge, UK)—1:2,000; α -ICP4 (Abcam, Cambridge, UK)—1:2,000; α -ADAR1 (Santa Cruz Biotech)—1:1,000; and α -ADAR1p150 (Cell Signaling Technology, Inc., Danvers, MA, USA)—1:1,000. Blots were washed for 30 min with TBS-0.05% Tween 20, and primary antibodies were detected using horseradish peroxidase-conjugated goat anti-mouse secondary antibody diluted 1:2,000 (Cell Signaling Technology, Inc.) and incubated at room temperature for 1 h. Blots were again washed for 30 min and visualized using the Amersham ECL reagent or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, MA, USA) and ChemiDoc MP (Bio-Rad Laboratories, Hercules, CA, USA).

Immunoprecipitation

HFF cells were seeded in 10-cm dishes in triplicates for the infection with HSV-1 KOS strain and extracted at 12 h.p.i. From each sample, a fraction (1/10) was taken for the total population of miRNAs before the immunoprecipitation protocol, and the rest of the sample was used for Ago and GFP immunoprecipitation (control). Immunoprecipitation of RNA bound to Argonaute (Ago) proteins was performed according to the Dynabeads Protein G protocol (Thermo Fisher Scientific). Briefly, Dynabeads were incubated with the 10 μ g of α -Ago antibody (Millipore) or α -GFP (Millipore) that acted as a negative control, diluted in PBS with 0.1% Tween-20 overnight at 4°C. After incubation, the supernatant was removed using a magnet, and beads were washed with PBS with 0.1% Tween-20. HFF samples were collected 12 h.p.i. in triplicates using NP-40 lysis buffer, and the supernatant from the cell lysis was added to the beads-antibody complex and incubated overnight at 4°C. After incubation, beads were washed and resuspended in TriReagent solution, and total RNA was extracted according to the manufacturer's instructions.

ACKNOWLEDGMENTS

The study was supported by Croatian Science Foundation grant IP-2020-02-2287 and DOK-2012-02.9152, and University of Rijeka support grant prirod-sp-23-502930 to I.J.;

AIRC IG grant (no. 13202) to A.G.; and National Institutes of Health grants NS105630 to A.R.C., T32GM008136 to S.A.D., and T32AI007046 to A.L.W.

Conceptualization: I.J.; methodology: I.J., M.C., H.J., O.V., and M.H.; validation: I.J., M.H., A.C., A.G., O.V., and D.C.; investigation: A.Z., A.P., M.C., F.R., H.J., C.G., A.W., S.D., and A.C.; resources: I.J., M.H., A.C., A.G., D.C., and O.V.; writing (original draft preparation): I.J.; writing (review and editing): all authors; supervision: I.J., A.C., D.C.: M.H., A.G., and O.V.; project administration: I.J.; funding acquisition: I.J., A.G. and M.H. All authors read and agreed to the published version of the manuscript.

AUTHOR AFFILIATIONS

¹Department of Biotechnology, University of Rijeka, Rijeka, Croatia

²Genetics Department and Biotechnology Institute, Biomedical Research Center (CIBM), University of Granada, Granada, Spain

³Faculty of Medicine, University of Rijeka, Rijeka, Croatia

⁴Laboratory for Advanced Genomics, Institute Ruđer Bošković, Zagreb, Croatia

⁵Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA

⁶Department of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

AUTHOR ORCID*s*

Igor Jurak  <http://orcid.org/0000-0002-7271-2643>

FUNDING

Funder	Grant(s)	Author(s)
Hrvatska Zaklada za Znanost (HRZZ)	IP-2020-02-2287, DOK-2012-02.9152	Igor Jurak
University of Rijeka	prirod-sp-23-502930	Igor Jurak
HHS National Institutes of Health (NIH)	NS105630, T32GM008136, T32AI007046	Anna R. Cliffe
Fondazione AIRC per la ricerca sul cancro ETS (AIRC)	13202	Angela Gallo

AUTHOR CONTRIBUTIONS

Andreja Zubković, Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review and editing | Adwait Parchure, Investigation, Writing – review and editing | Mia Cesarec, Investigation, Writing – review and editing | Antun Ferenčić, Investigation, Methodology, Writing – review and editing | Filip Rokić, Investigation, Methodology | Hrvoje Jakovac, Investigation, Methodology | Abigail L. Whitford, Investigation, Methodology, Writing – review and editing | Sara A. Dochnal, Investigation, Writing – review and editing | Anna R. Cliffe, Funding acquisition, Investigation, Resources, Writing – review and editing | Dražen Cuculić, Funding acquisition, Resources, Writing – review and editing | Oliver Vugrek, Formal analysis, Funding acquisition, Methodology, Resources, Writing – review and editing | Michael Hackenberg, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Writing – original draft, Writing – review and editing | Igor Jurak, Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing – original draft, Writing – review and editing.

DATA AVAILABILITY

Raw sequencing data were deposited at the NCBI Sequence Read Archive under BioProject accession number [PRJNA998693](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA998693).

ETHICS APPROVAL

The ethics committee of the Faculty of Medicine in Rijeka, University of Rijeka, approved the use of autopsy samples for the present study.

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Supplemental Information (JV100730-23-s0001.pdf). Predictions, additional experiments.

REFERENCES

- Bartel DP. 2018. Metazoan microRNAs. *Cell* 173:20–51. <https://doi.org/10.1016/j.cell.2018.03.006>
- Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* 136:215–233. <https://doi.org/10.1016/j.cell.2009.01.002>
- Friedman RC, Farh K-H, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res* 19:92–105. <https://doi.org/10.1101/gr.082701.108>
- Smolarz B, Durczyński A, Romanowicz H, Szyłło K, Hogendorf P. 2022. miRNAs in cancer (review of literature). *Int J Mol Sci* 23:2805. <https://doi.org/10.3390/ijms23052805>
- Chen S, Deng Y, Pan D. 2022. MicroRNA regulation of human herpesvirus latency. *Viruses* 14:1215. <https://doi.org/10.3390/v14061215>
- Gottwein E, Cullen BR. 2008. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. *Cell Host & Microbe* 3:375–387. <https://doi.org/10.1016/j.chom.2008.05.002>
- Jurak I, Griffiths A, Coen DM. 2011. Mammalian alphaherpesvirus miRNAs. *Biochim Biophys Acta (BBA) - Gene Regul Mech* 1809:641–653. <https://doi.org/10.1016/j.bbagr.2011.06.010>
- Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature* 454:780–783. <https://doi.org/10.1038/nature07103>
- Jurak Igor, Kramer MF, Mellor JC, van Lint AL, Roth FP, Knipe DM, Coen DM. 2010. Numerous conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2. *J Virol* 84:4659–4672. <https://doi.org/10.1128/JVI.02725-09>
- Umbach JL, Nagel MA, Cohrs RJ, Gilden DH, Cullen BR. 2009. Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. *J Virol* 83:10677–10683. <https://doi.org/10.1128/JVI.01185-09>
- Umbach JL, Wang K, Tang S, Krause PR, Mont EK, Cohen JI, Cullen BR. 2010. Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. *J Virol* 84:1189–1192. <https://doi.org/10.1128/JVI.01712-09>
- Han ZY, Liu XJ, Chen XQ, Zhou XS, Du T, Roizman B, Zhou GY. 2016. miR-H28 and miR-H29 expressed late in productive infection are exported and restrict HSV-1 replication and spread in recipient cells. *Proc Natl Acad Sci U S A* 113:E894–901. <https://doi.org/10.1073/pnas.1525674113>
- Matesic MP. 2020. Puzzling functions of HSV-1 miRNAs in productive and latent infection. *Period Biol* 121–122:107–113. <https://doi.org/10.18054/pb.v121-122i3-4.10561>
- Cliffe AR, Garber DA, Knipe DM. 2009. Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. *J Virol* 83:8182–8190. <https://doi.org/10.1128/JVI.00712-09>
- Chen SH, Kramer MF, Schaffer PA, Coen DM. 1997. A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. *J Virol* 71:5878–5884. <https://doi.org/10.1128/JVI.71.8.5878-5884.1997>
- Perng GC, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, Slanina SM, Hofman FM, Ghiasi H, Nesburn AB, Wechsler SL. 2000. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. *Science* 287:1500–1503. <https://doi.org/10.1126/science.287.5457.1500>
- Thompson RL, Sawtell NM. 2001. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. *J Virol* 75:6660–6675. <https://doi.org/10.1128/JVI.75.14.6660-6675.2001>
- Wang Q-Y, Zhou C, Johnson KE, Colgrove RC, Coen DM, Knipe DM. 2005. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. *Proc Natl Acad Sci U S A* 102:16055–16059. <https://doi.org/10.1073/pnas.0505850102>
- Kramer MF, Jurak I, Pesola JM, Boissel S, Knipe DM, Coen DM. 2011. Herpes simplex virus 1 microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia. *Virology* 417:239–247. <https://doi.org/10.1016/j.virol.2011.06.027>
- Tang S, Bertke AS, Patel A, Wang K, Cohen JI, Krause PR. 2008. An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. *Proc Natl Acad Sci U S A* 105:10931–10936. <https://doi.org/10.1073/pnas.0801845105>
- Tang S, Patel A, Krause PR. 2009. Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs. *J Virol* 83:1433–1442. <https://doi.org/10.1128/JVI.01723-08>
- Du T, Han Z, Zhou G, Roizman B. 2015. Patterns of accumulation of miRNAs encoded by herpes simplex virus during productive infection, latency, and on reactivation. *Proc Natl Acad Sci U S A* 112:E49–55. <https://doi.org/10.1073/pnas.1422657112>
- Du T, Zhou G, Roizman B. 2011. HSV-1 gene expression from reactivated ganglia is disordered and concurrent with suppression of latency-associated transcript and miRNAs. *Proc Natl Acad Sci U S A* 108:18820–18824. <https://doi.org/10.1073/pnas.1117203108>
- Barrozo ER, Nakayama S, Singh P, Vanni EAH, Arvin AM, Neumann DM, Bloom DC. 2020. Deletion of herpes simplex virus 1 microRNAs miR-H1 and miR-H6 impairs reactivation. *J Virol* 94:e00639-20. <https://doi.org/10.1128/JVI.00639-20>
- Lanfranca MP, Mostafa HH, Davido DJ. 2014. HSV-1 ICP0: an E3 ubiquitin ligase that counteracts host intrinsic and innate immunity. *Cells* 3:438–454. <https://doi.org/10.3390/cells3020438>
- Rodriguez MC, Dybas JM, Hughes J, Weitzman MD, Boutell C. 2020. The HSV-1 ubiquitin ligase ICP0: modifying the cellular proteome to promote infection. *Virus Res* 285:198015. <https://doi.org/10.1016/j.virusres.2020.198015>

27. Wilcox DR, Longnecker R, Racaniello V. 2016. The herpes simplex virus neurovirulence factor γ 34.5: revealing virus-host interactions. *PLoS Pathog* 12:e1005449. <https://doi.org/10.1371/journal.ppat.1005449>
28. Pan D, Pesola JM, Li G, McCarron S, Coen DM. 2017. Mutations inactivating herpes simplex virus 1 microRNA miR-H2 do not detectably increase *ICP0* gene expression in infected cultured cells or mouse trigeminal ganglia. *J Virol* 91:e02001-16. <https://doi.org/10.1128/JVI.02001-16>
29. Barrozo ER, Nakayama S, Singh P, Neumann DM, Bloom DC, Sandri-Goldin RM. 2021. Herpes simplex virus 1 microRNA miR-H8 is dispensable for latency and reactivation *in vivo*. *J Virol* 95. <https://doi.org/10.1128/JVI.02179-20>
30. Flores O, Nakayama S, Whisnant AW, Javanbakht H, Cullen BR, Bloom DC. 2013. Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture. *J Virol* 87:6589–6603. <https://doi.org/10.1128/JVI.00504-13>
31. Jiang X, Brown D, Osorio N, Hsiang C, Li L, Chan L, BenMohamed L, Wechsler SL. 2015. A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation. *J Neurovirol* 21:199–209. <https://doi.org/10.1007/s13365-015-0319-1>
32. Huang R, Wu J, Zhou X, Jiang H, Guoying Zhou G, Roizman B. 2019. Herpes simplex virus 1 microRNA miR-H28 exported to uninfected cells in exosomes restricts cell-to-cell virus spread by inducing gamma interferon mRNA. *J Virol* 93:e01005-19. <https://doi.org/10.1128/JVI.01005-19>
33. Cokarić Brdovčak M, Zubković A, Jurak I. 2018. Herpes simplex virus 1 deregulation of host microRNAs. *Noncoding RNA* 4:36. <https://doi.org/10.3390/ncrna4040036>
34. Sun B, Yang X, Hou F, Yu X, Wang Q, Oh HS, Raja P, Pesola JM, Vanni EAH, McCarron S, Morris-Love J, Ng AHM, Church GM, Knipe DM, Coen DM, Pan D. 2021. Regulation of host and virus genes by neuronal miR-138 favours herpes simplex virus 1 latency. *Nat Microbiol* 6:682–696. <https://doi.org/10.1038/s41564-020-00860-1>
35. Pan D, Flores O, Umbach JL, Pesola JM, Bentley P, Rosato PC, Leib DA, Cullen BR, Coen DM. 2014. A neuron-specific host microRNA targets herpes simplex virus-1 *ICP0* expression and promotes latency. *Cell Host Microbe* 15:446–456. <https://doi.org/10.1016/j.chom.2014.03.004>
36. Song B, Shiromoto Y, Minakuchi M, Nishikura K. 2022. The role of RNA editing enzyme ADAR1 in human disease. *Wiley Interdiscip Rev RNA* 13:e1665. <https://doi.org/10.1002/wrna.1665>
37. Nishikura K. 2016. A-to-I editing of coding and non-coding RNAs by ADARs. *Nat Rev Mol Cell Biol* 17:83–96. <https://doi.org/10.1038/nrm.2015.4>
38. Pfaller CK, George CX, Samuel CE. 2021. Adenosine deaminases acting on RNA (ADARs) and viral infections. *Annu Rev Virol* 8:239–264. <https://doi.org/10.1146/annurev-virology-091919-065320>
39. Tomaselli S, Galeano F, Locatelli F, Gallo A. 2015. ADARs and the balance game between virus infection and innate immune cell response. *Curr Issues Mol Biol* 17:37–51.
40. Rosani U, Bortoletto E, Montagnani C, Venier P, Einav S. 2022. ADAR-editing during ostreid herpesvirus 1 infection in *Crassostrea gigas*: facts and limitations. *mSphere* 7:e0001122. <https://doi.org/10.1128/msphere.00011-22>
41. Prazsák I, Moldován N, Balázs Z, Tombácz D, Megyeri K, Szűcs A, Csabai Z, Boldogkői Z. 2018. Long-read sequencing uncovers a complex transcriptome topology in varicella zoster virus. *BMC Genomics* 19:873. <https://doi.org/10.1186/s12864-018-5267-8>
42. Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. 2007. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. *J Virol* 81:13544–13551. <https://doi.org/10.1128/JVI.01521-07>
43. Rajendren S, Ye X, Dunker W, Richardson A, Karizjolic J. 2023. The cellular and KSHV A-to-I RNA editome in primary effusion lymphoma and its role in the viral lifecycle. *Nat Commun* 14:1367. <https://doi.org/10.1038/s41467-023-37105-8>
44. Zhang H, Ni G, Damania B. 2020. ADAR1 facilitates KSHV lytic reactivation by modulating the RLR-dependent signaling pathway. *Cell Reports* 31:107564. <https://doi.org/10.1016/j.celrep.2020.107564>
45. Iizasa H, Wulff B-E, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A, Iwakiri D, Takada K, Wiedmer A, Showe L, Lieberman P, Nishikura K. 2010. Editing of epstein-barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. *J Biol Chem* 285:33358–33370. <https://doi.org/10.1074/jbc.M110.138362>
46. Lei T, Yuen KS, Tsao SW, Chen H, Kok KH, Jin DY. 2013. Perturbation of biogenesis and targeting of epstein-barr virus-encoded miR-Bart3 microRNA by adenosine-to-inosine editing. *J Gen Virol* 94:2739–2744. <https://doi.org/10.1099/vir.0.056226-0>
47. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, van Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T. 2005. Identification of microRNAs of the herpesvirus family. *Nat Methods* 2:269–276. <https://doi.org/10.1038/nmeth746>
48. Nachmani D, Zimmermann A, Oiknine Djan E, Weisblum Y, Livneh Y, Khanh Le VT, Galun E, Horejsi V, Isakov O, Shomron N, Wolf DG, Hengel H, Mandelboim O. 2014. MicroRNA editing facilitates immune elimination of HCMV infected cells. *PLoS Pathog* 10:e1003963. <https://doi.org/10.1371/journal.ppat.1003963>
49. Aparicio-Puerta E, Lebrón R, Rueda A, Gómez-Martín C, Giannoukakis S, Jaspez D, Medina JM, Zubković A, Jurak I, Fromm B, Marchal JA, Oliver J, Hackenberg M. 2019. sRNAbench and sRNAtoolbox 2019: intuitive fast small RNA profiling and differential expression. *Nucleic Acids Res* 47:W530–W535. <https://doi.org/10.1093/nar/gkz415>
50. Cokarić Brdovčak M, Zubković A, Ferenčić A, Šoša I, Stemberga V, Cuculić D, Rokić F, Vugrek O, Hackenberg M, Jurak I. 2018. Herpes simplex virus 1 miRNA sequence variations in latently infected human trigeminal ganglia. *Virus Res* 256:90–95. <https://doi.org/10.1016/j.virusres.2018.08.002>
51. Tian G, Yin X, Luo H, Xu X, Bolund L, Zhang X, Gan S-Q, Li N. 2010. Sequencing bias: comparison of different protocols of microRNA library construction. *BMC Biotechnol* 10:64. <https://doi.org/10.1186/1472-6750-10-64>
52. Linsen SEV, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E. 2009. Limitations and possibilities of small RNA digital gene expression profiling. *Nat Methods* 6:474–476. <https://doi.org/10.1038/nmeth0709-474>
53. Blow MJ, Grocock RJ, van Dongen S, Enright AJ, Dicks E, Futreal PA, Wooster R, Stratton MR. 2006. RNA editing of human microRNAs. *Genome Biol* 7:R27. <https://doi.org/10.1186/gb-2006-7-4-r27>
54. Picardi E, Manzari C, Mastropasqua F, Aiello I, D'Erchia AM, Pesole G. 2015. Profiling RNA editing in human tissues: towards the inosinome Atlas. *Sci Rep* 5:14941. <https://doi.org/10.1038/srep14941>
55. Flores O, Kennedy EM, Skalsky RL, Cullen BR. 2014. Differential RISC association of endogenous human microRNAs predicts their inhibitory potential. *Nucleic Acids Res* 42:4629–4639. <https://doi.org/10.1093/nar/gkt1393>
56. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. *Cell* 115:787–798. [https://doi.org/10.1016/s0092-8674\(03\)01018-3](https://doi.org/10.1016/s0092-8674(03)01018-3)
57. Chen Y, Wang X. 2020. miRDB: an online database for prediction of functional microRNA targets. *Nucleic Acids Res* 48:D127–D131. <https://doi.org/10.1093/nar/gkz757>
58. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10:R25. <https://doi.org/10.1186/gb-2009-10-3-r25>
59. Jurak I, Silverstein LB, Sharma M, Coen DM. 2012. Herpes simplex virus is equipped with RNA- and protein-based mechanisms to repress expression of ATRX, an effector of intrinsic immunity. *J Virol* 86:10093–10102. <https://doi.org/10.1128/JVI.00930-12>
60. Kim K, Calabrese P, Wang S, Qin C, Rao Y, Feng P, Chen XS. 2022. The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness. *Sci Rep* 12:14972. <https://doi.org/10.1038/s41598-022-19067-x>
61. Dochnal S, Merchant HY, Schinlever AR, Babnis A, Depledge DP, Wilson AC, Cliffe AR. 2022. DLK-dependent biphasic reactivation of herpes simplex virus latency established in the absence of antivirals. *J Virol* 96:e0050822. <https://doi.org/10.1128/jvi.00508-22>
62. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC, Li JB, Seeburg PH, Walkley CR. 2015. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. *Science* 349:1115–1120. <https://doi.org/10.1126/science.aac7049>

63. Wang IX, So E, Devlin JL, Zhao Y, Wu M, Cheung VG. 2013. ADAR regulates RNA editing, transcript stability, and gene expression. *Cell Reports* 5:849–860. <https://doi.org/10.1016/j.celrep.2013.10.002>
64. Zubković A, Žarak I, Ratkaj I, Rokić F, Jekić M, Pribanić Matešić M, Lebrón R, Gómez-Martín C, Lisnić B, Lisnić VJ, Jonjić S, Pan D, Vugrek O, Hackenberg M, Jurak I. 2022. The virus-induced upregulation of the miR-183/96/182 cluster and the FoxO family protein members are not required for efficient replication of HSV-1. *Viruses* 14:1661. <https://doi.org/10.3390/v14081661>
65. Whitford AL, Clinton CA, Kennedy EBL, Dochnal SA, Suzich JB, Cliffe AR. 2022. *Ex Vivo* herpes simplex virus reactivation involves a dual leucine zipper kinase-dependent wave of lytic gene expression that is independent of histone demethylase activity and viral genome synthesis. *J Virol* 96:e0047522. <https://doi.org/10.1128/jvi.00475-22>
66. Sandri-Goldin RM, Sekulovich RE, Leary K. 1987. The α protein ICP0 does not appear to play a major role in the regulation of herpes simplex virus gene expression during infection in tissue culture. *Nucleic Acids Res* 15:905–919. <https://doi.org/10.1093/nar/15.3.905>
67. Sekulovich RE, Leary K, Sandri-Goldin RM. 1988. The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0. *J Virol* 62:4510–4522. <https://doi.org/10.1128/JVI.62.12.4510-4522.1988>
68. Aparicio-Puerta E, Gómez-Martín C, Giannoukakos S, Medina JM, Scheepbouwer C, García-Moreno A, Carmona-Saez P, Fromm B, Pegtel M, Keller A, Marchal JA, Hackenberg M. 2022. sRNAbench and sRNAtoolbox 2022 update: accurate miRNA and sncRNA profiling for model and non-model organisms. *Nucleic Acids Res* 50:W710–W717. <https://doi.org/10.1093/nar/gkac363>
69. Rueda A, Barturen G, Lebrón R, Gómez-Martín C, Alganza Á, Oliver JL, Hackenberg M. 2015. sRNAtoolbox: an integrated collection of small RNA research tools. *Nucleic Acids Res* 43:W467–73. <https://doi.org/10.1093/nar/gkv555>
70. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 120:15–20. <https://doi.org/10.1016/j.cell.2004.12.035>
71. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. 2004. Fast and effective prediction of microRNA/target duplexes. *RNA* 10:1507–1517. <https://doi.org/10.1261/rna.5248604>